Valuation: Natera, Inc.

Market Cap 38.87B 33.98B 31.36B 28.89B 54.49B 3,742B 55.68B 375B 147B 1,832B 146B 143B 6,310B P/E 2026 *
-163x
P/E 2027 * -1,175x
Enterprise Value 37.82B 33.07B 30.52B 28.11B 53.02B 3,641B 54.18B 365B 143B 1,783B 142B 139B 6,140B EV / Sales 2026 *
13.5x
EV / Sales 2027 * 11.3x
Free-Float
97.02%
Yield 2026 *
-
Yield 2027 * -
1 day+0.58%
1 week+0.53%
Current month-0.02%
1 month+17.28%
3 months+30.23%
6 months+17.36%
Current year+18.46%
1 week 261.63
Extreme 261.63
282
1 month 219.5
Extreme 219.5
288.04
Current year 181
Extreme 181
288.04
1 year 131.81
Extreme 131.8106
288.04
3 years 36.9
Extreme 36.9
288.04
5 years 26.1
Extreme 26.1
288.04
10 years 7.35
Extreme 7.35
288.04
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap.
7/13/26 Sell

Founder

-3,150 0.0022%
7/6/26 Sell

Founder

-1,000 0.0007%
7/1/26 Sell

General Counsel

-16,800 0.0117%
Change 5-day change 1-year change 3-year change Capi.($)
+0.58%+0.53%+95.39%+457.61% 38.87B
+0.50%+2.37%+16.26%+33.21% 23.24B
+0.64%+3.01%-19.97%-39.27% 7.55B
-1.27%-5.20%+8.18%+82.59% 4.89B
-2.61%-0.32%+13.16%+44.30% 2.93B
-1.55%+3.54%+134.13%-14.91% 1.9B
-13.79%-10.75%+16.53%-21.12% 1.65B
-5.48%+7.11%-9.97%-63.27% 1.8B
+2.90%-3.29%-18.48%+756.68% 1.88B
+7.73%+1.04%+29.81%+7.52% 1.76B
Average -1.24%-0.59%+26.50%+124.33% 8.65B
Weighted average by Cap. +0.10%+0.72%+49.67%+231.96%

Financials

2026 *2027 *
Net sales 2.8B 2.45B 2.26B 2.08B 3.92B 269B 4.01B 26.98B 10.6B 132B 10.5B 10.27B 454B 3.33B 2.91B 2.69B 2.47B 4.67B 320B 4.77B 32.1B 12.61B 157B 12.5B 12.22B 540B
Net income -225M -197M -181M -167M -315M -21.64B -322M -2.17B -852M -10.6B -844M -826M -36.49B -28.71M -25.1M -23.16M -21.34M -40.25M -2.76B -41.13M -277M -109M -1.35B -108M -105M -4.66B
Net Debt -1.05B -917M -846M -779M -1.47B -101B -1.5B -10.11B -3.97B -49.43B -3.94B -3.85B -170B -1.32B -1.15B -1.07B -981M -1.85B -127B -1.89B -12.73B -5B -62.21B -4.96B -4.85B -214B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-07-17 US$271.39 +0.58% 1,014,525
26-07-16 US$269.83 -2.72% 948,974
26-07-15 US$277.37 +1.73% 867,755
26-07-14 US$272.66 -0.08% 954,842
26-07-13 US$272.89 +1.09% 1,528,001
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
271.39USD
Average target price
282.14USD
Spread / Average Target
+3.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock